GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chengdu Kanghong Pharmaceutical Group Co 002773.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

23.45

+1.91%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.59bn

FY2016FY2025

Net income

CN¥1.16bn

FY2016FY2025

Free cash flow

CN¥1.24bn

FY2016FY2025

Shareholders' equity

CN¥9.30bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.59bnCN¥4.45bnCN¥3.96bnCN¥3.39bnCN¥3.61bnCN¥3.30bnCN¥3.26bnCN¥2.92bnCN¥2.79bnCN¥2.54bn
Gross profitCN¥4.12bnCN¥3.98bnCN¥3.52bnCN¥3.00bnCN¥3.25bnCN¥2.97bnCN¥2.99bnCN¥2.69bnCN¥2.52bnCN¥2.30bn
Research and developmentCN¥533.1mCN¥594.0mCN¥421.7mCN¥374.0mCN¥1.01bnCN¥1.68bnCN¥286.9mCN¥230.4mCN¥191.9mCN¥122.2m
Operating incomeCN¥1.30bnCN¥1.38bnCN¥1.26bnCN¥1.02bnCN¥355.2m−CN¥512.3mCN¥820.8mCN¥796.2mCN¥787.5mCN¥551.2m
Net incomeCN¥1.16bnCN¥1.19bnCN¥1.04bnCN¥896.7mCN¥421.1m−CN¥269.9mCN¥718.2mCN¥694.9mCN¥644.2mCN¥496.8m
Diluted earnings per share1.261.291.141.000.47-0.310.810.790.730.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥9.92bnCN¥9.34bnCN¥8.53bnCN¥7.72bnCN¥6.96bnCN¥7.00bnCN¥5.83bnCN¥5.19bnCN¥4.59bnCN¥3.76bn
Cash and short-term investments—CN¥5.69bnCN¥4.70bnCN¥3.69bnCN¥3.14bnCN¥3.33bnCN¥2.28bnCN¥2.71bnCN¥3.10bnCN¥2.65bn
Total liabilitiesCN¥645.2mCN¥695.1mCN¥717.8mCN¥813.9mCN¥851.1mCN¥1.25bnCN¥1.21bnCN¥1.11bnCN¥1.04bnCN¥853.3m
Debt—CN¥3.5mCN¥1.5mCN¥3.3mCN¥4.4mCN¥1.1mCN¥277.6mCN¥342.2mCN¥395.8mCN¥191.1m
Shareholders' equityCN¥9.30bnCN¥8.65bnCN¥7.80bnCN¥6.90bnCN¥6.09bnCN¥5.76bnCN¥4.62bnCN¥4.08bnCN¥3.54bnCN¥2.90bn
Shares outstanding921m923m919m899m902m873m883m879m879m869m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.50bnCN¥1.41bnCN¥1.22bnCN¥925.2mCN¥494.1mCN¥273.3mCN¥812.1mCN¥350.9mCN¥766.9mCN¥846.3m
Capital spending−CN¥262.5m−CN¥159.4m−CN¥138.9m−CN¥355.2m−CN¥569.4m−CN¥617.1m−CN¥962.9m−CN¥458.4m−CN¥312.9m−CN¥170.2m
Free cash flowCN¥1.24bnCN¥1.25bnCN¥1.08bnCN¥569.9m−CN¥75.3m−CN¥343.8m−CN¥150.7m−CN¥107.6mCN¥454.0mCN¥676.1m
Dividends paid−CN¥552.7m−CN¥349.4m−CN¥137.9m−CN¥91.9m−CN¥91.9m−CN¥244.6m−CN¥188.1m−CN¥188.5m−CN¥100.8m−CN¥89.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.13bnCN¥1.05bnCN¥961.3mCN¥1.17bnCN¥1.25bnCN¥1.20bnCN¥1.04bnCN¥1.12bn
Gross profitCN¥1.00bnCN¥927.8mCN¥846.3mCN¥1.07bnCN¥1.13bnCN¥1.07bnCN¥917.2mCN¥1.01bn
Operating incomeCN¥293.6mCN¥347.5mCN¥117.8mCN¥339.0mCN¥399.0mCN¥465.6mCN¥232.6mCN¥328.2m
Net incomeCN¥257.3mCN¥307.5mCN¥130.1mCN¥303.2mCN¥329.7mCN¥400.0mCN¥217.5mCN¥281.5m
Diluted earnings per share0.280.330.140.330.360.430.240.30
Cash from operations———CN¥504.0mCN¥482.0mCN¥433.0mCN¥184.0mCN¥450.0m
Capital spending−CN¥74.0m−CN¥69.0m−CN¥83.0m−CN¥105.0m−CN¥27.0m−CN¥47.0m−CN¥41.0m−CN¥41.0m
Free cash flow———CN¥399.0mCN¥455.0mCN¥386.0mCN¥143.0mCN¥409.0m
Total assetsCN¥9.94bnCN¥10.21bnCN¥9.92bnCN¥9.87bnCN¥9.53bnCN¥9.67bnCN¥9.34bnCN¥9.21bn
Cash and short-term investments———CN¥6.39bnCN¥6.00bnCN¥6.08bnCN¥5.69bnCN¥5.55bn
Debt———CN¥1.5mCN¥1.7mCN¥1.4m——
Shareholders' equityCN¥9.21bnCN¥9.61bnCN¥9.30bnCN¥9.17bnCN¥8.86bnCN¥9.05bnCN¥8.65bnCN¥8.44bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2014FY2013
Gross margin89.8%89.5%88.9%88.4%90.1%90.0%—————
Operating margin28.3%31.0%31.9%30.0%9.9%-15.5%—————
Net margin25.4%26.8%26.4%26.5%11.7%-8.2%—————
Return on equity12.5%13.8%13.4%13.0%6.9%-4.7%—————
Return on assets11.7%12.8%12.2%11.6%6.1%-3.9%—————
Free cash flow yield9.5%8.4%7.3%7.1%5.8%5.1%—————
Revenue growth3.0%12.5%16.8%-6.0%9.4%1.2%—————
Earnings growth-2.4%14.0%16.5%112.9%-256.0%-137.6%—————
Current ratio11.77x9.60x8.11x6.10x5.54x4.04x—————
Debt to equity—0.00x————0.06x0.10x0.03x0.00x0.00x
Equity ratio93.7%92.6%91.5%89.4%87.5%82.2%—————
Interest coverage—2440.44x8363.74x4425.51x388.09x-451.29x1432.89x————
R&D as a share of sales11.6%13.3%10.7%11.0%28.0%50.9%—————
Buybacks as a share of market value0.2%-0.4%-2.3%0.3%-3.3%1.2%—————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.6%6.8%8.3%
Operating income8.5%—11.5%
Net income9.1%—11.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin89.7%89.2%89.5%90.0%
Operating margin29.6%30.2%20.6%22.2%
Net margin26.0%26.2%19.1%20.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings23.715.216.215.743.6-155.845.533.264.876.4
Price to sales6.04.14.34.25.112.810.07.915.014.9

Dividends and splits

Per share, in the currency the company pays

Paid for 10 years. Last went ex-dividend on 9 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.700.600.380.150.100.100.280.215
  • 13-for-10 split · 6 Jun 2019
  • 3-for-2 split · 8 Jun 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.